Drug Information

Drug General Information
Drug ID
D0H3JF
Former ID
DNCL002201
Drug Name
VTX-2337
Drug Type
Small molecular drug
Indication Allergy [ICD9: 995.3; ICD10:T78.4] Discontinued in Phase 2 [524026]
Company
VentiRx Pharmaceuticals
Formula
C28H34N4O2
PubChem Compound ID
16049404
Target and Pathway
Target(s) Toll-like receptor 8 Target Info Modulator [550276]
KEGG Pathway Toll-like receptor signaling pathway
NetPath Pathway Leptin Signaling Pathway
TCR Signaling Pathway
PANTHER Pathway Toll receptor signaling pathway
Reactome Trafficking and processing of endosomal TLR
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
MyD88 dependent cascade initiated on endosome
WikiPathways Toll-like receptor signaling pathway
Toll-Like Receptors Cascades
MyD88 dependent cascade initiated on endosome
Trafficking and processing of endosomal TLR
Regulation of toll-like receptor signaling pathway
References
Ref 524026ClinicalTrials.gov (NCT01666444) VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. U.S. National Institutes of Health.
Ref 550276Clinical pipeline report, company report or official report of Array BioPharma (Drug: Motolimod / VTX2337).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.